Castleman Disease with Corey Casper, MD

Bexobrutideg, a first-in-class Bruton’s tyrosine kinase degrader, has been granted orphan drug designation from the FDA in Waldenström macroglobulinemia.

David A. Russler-Germain, MD, PhD, discusses his path in oncology and the many advancements shaping lymphoma treatment today.

Fixed-duration glofitamab combined with polatuzumab vedotin achieved high response rates and sustained remissions in heavily pretreated relapsed/refractory large B-cell lymphoma.

In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.

During a Case-Based Roundtable® event, Christopher Maisel, MD, discussed third- and fourth-line therapy and barriers to bispecific therapy use in diffuse large B-cell lymphoma in the second article of a 2-part series.

The field of Hodgkin lymphoma is undergoing significant advancements, with new drugs entering the frontline and personalized treatment approaches emerging.